Table 1 Characteristics of studies included in the present meta-analysis
Detection of FBXW7 mutation/expression | Study | Study Region | Recruitment time | No. of patients | Clinical Stage | FBXW7 status method | Cut off | Antibody source | Dilution | Case: Low/High (MT/WT)a | Median follow-up months | Analysis method | OS HR(95%CI) | DFS HR(95%CI) | Quality score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mutation | Chang, 2015 [11] | Taiwan | 2000-2009 | 1519 | TNM I-IV | MassArray | NA | NA | NA | 114/1405 | NA | Univariate | 1.00 (0.98–1.02) | NA | 8 |
Mouradov, 2013 [19] | Australia | 2002-2004 | 822 | TNM II-III | Sanger sequencing | NA | NA | NA | 41/781 | 32.2 | Univariate | 0.96 (0.45–2.06) | NA | 7 | |
Korphaisarn, 2017 [16] | USA | 2009-2015 | 527 | TNM IV | NGS | NA | NA | NA | 43/484 | 30.4 | Multivariate | 2.00 (1.27–3.16) | NA | 8 | |
Iwatsuki, 2010 [14] | Japan | 1993-1999 | 93 | Duke A-D | qRT-PCR | Median | NA | NA | 46/47 | 36 | Multivariate | 1.98 (1.26–3.27) | NA | 7 | |
Gao, 2019 [12] | China | 2015-2016 | 207 | TNM I-IV | MiSeq | NA | NA | NA | 33/174 | 23 | Univariate | 0.59 (0.21–1.68) | 0.75 (0.32–1.79) | 7 | |
Expression | He, 2019 [13] | China | 2009-2011 | 140 | TNM I-IV | IHC | NA | Abcam, USA | 1:500 | 84/56 | NA | Univariate | 2.30 (0.92–5.76) | 2.45 (1.22–4.92) | 6 |
Liu, 2018 [18] | China | 2010-2015 | 509 | TNM I-IV | IHC | Score 4 | Abcam, USA | 1:200 | 359/150 | NA | Univariate | 2.22 (1.40–3.45) | NA | 6 | |
Li, 2018 [17] | China | 2007-2009 | 276 | TNM I-IV | IHC | Score 1 | Bethyl, USA | NA | 60/216 | NA | Multivariate | 3.57 (2.23–5.71) | 4.63 (2.65–8.13) | 7 | |
Tang, 2016 [24] | China | 2011-2011 | 50 | Duke A-D | IHC | score 3 | Santa Cruz, USA | 1:60 | 23/27 | NA | Univariate | 1.04 (0.12–9.42) | NA | 7 | |
Kawashita, 2017 [15] | Japan | 2001-2009 | 56 | NA | IHC | Score 3 | Abcam, USA | 1:100 | 24/32 | 55 | Univariate | 1.98 (0.42–9.26) | 1.50 (0.79–2.85) | 7 |